NTLA
Price
$8.19
Change
+$0.10 (+1.24%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
860.23M
7 days until earnings call
SLDB
Price
$3.67
Change
+$0.11 (+3.09%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
265.8M
Ad is loading...

NTLA vs SLDB

Header iconNTLA vs SLDB Comparison
Open Charts NTLA vs SLDBBanner chart's image
Intellia Therapeutics
Price$8.19
Change+$0.10 (+1.24%)
Volume$37.15K
Capitalization860.23M
Solid Biosciences
Price$3.67
Change+$0.11 (+3.09%)
Volume$18.12K
Capitalization265.8M
NTLA vs SLDB Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. SLDB commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and SLDB is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (NTLA: $8.09 vs. SLDB: $3.55)
Brand notoriety: NTLA and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 69% vs. SLDB: 48%
Market capitalization -- NTLA: $860.23M vs. SLDB: $265.8M
NTLA [@Biotechnology] is valued at $860.23M. SLDB’s [@Biotechnology] market capitalization is $265.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileSLDB’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • SLDB’s FA Score: 1 green, 4 red.
According to our system of comparison, SLDB is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 4 bearish.
  • SLDB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both NTLA and SLDB are a good buy in the short-term.

Price Growth

NTLA (@Biotechnology) experienced а +17.93% price change this week, while SLDB (@Biotechnology) price change was +40.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

NTLA is expected to report earnings on Jul 31, 2025.

SLDB is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($860M) has a higher market cap than SLDB($266M). SLDB YTD gains are higher at: -11.250 vs. NTLA (-30.617). SLDB has higher annual earnings (EBITDA): -121.9M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. SLDB (149M). SLDB has less debt than NTLA: SLDB (24.2M) vs NTLA (210M). NTLA has higher revenues than SLDB: NTLA (57.9M) vs SLDB (0).
NTLASLDBNTLA / SLDB
Capitalization860M266M323%
EBITDA-523.98M-121.9M430%
Gain YTD-30.617-11.250272%
P/E RatioN/AN/A-
Revenue57.9M0-
Total Cash602M149M404%
Total Debt210M24.2M868%
FUNDAMENTALS RATINGS
NTLA vs SLDB: Fundamental Ratings
NTLA
SLDB
OUTLOOK RATING
1..100
420
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9195
PRICE GROWTH RATING
1..100
8765
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (27) in the Biotechnology industry is in the same range as SLDB (36). This means that NTLA’s stock grew similarly to SLDB’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SLDB (100). This means that NTLA’s stock grew similarly to SLDB’s over the last 12 months.

NTLA's SMR Rating (91) in the Biotechnology industry is in the same range as SLDB (95). This means that NTLA’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's Price Growth Rating (65) in the Biotechnology industry is in the same range as NTLA (87). This means that SLDB’s stock grew similarly to NTLA’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for NTLA (100). This means that SLDB’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLASLDB
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARBFX13.120.06
+0.46%
Arbitrage R
MMIEX13.31N/A
N/A
MM S&P 500® Index Svc
MUXYX23.25N/A
N/A
Victory S&P 500 Index Y
SFGCX12.58N/A
N/A
NAA World Equity Income C
HBLSX14.12N/A
N/A
Hartford Balanced Income R4

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with PRME. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
+3.50%
PRME - SLDB
47%
Loosely correlated
+4.14%
NTLA - SLDB
45%
Loosely correlated
-2.65%
EDIT - SLDB
44%
Loosely correlated
N/A
BEAM - SLDB
43%
Loosely correlated
+3.87%
ALLO - SLDB
43%
Loosely correlated
+1.26%
More